Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31.

Pilepich, M V; Caplan, R; Byhardt, R W; Lawton, C A; Gallagher, M J; Mesic, J B; Hanks, G E; Coughlin, C T; Porter, A; Shipley, W U; Grignon, D

Pilepich, M V; Caplan, R; Byhardt, R W; Lawton, C A; Gallagher, M J; Mesic, J B; Hanks, G E; Coughlin, C T; Porter, A; Shipley, W U; Grignon, D.

Affiliation

Pilepich MV; Catherine McAuley Health Systems, Ann Arbor, MI, USA.

J Clin Oncol ; 15(3): 1013-21, 1997 Mar.

Article in En | MEDLINE | ID: mdl-9060541

Subject(s)

Adenocarcinoma/drug therapy; Adenocarcinoma/radiotherapy; Antineoplastic Agents, Hormonal/therapeutic use; Goserelin/therapeutic use; Prostatic Neoplasms/drug therapy; Prostatic Neoplasms/radiotherapy; Chemotherapy, Adjuvant; Follow-Up Studies; Humans; Male; Prognosis; Survival Analysis

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Prostatic Neoplasms / Adenocarcinoma / Goserelin / Antineoplastic Agents, Hormonal Type of study: Clinical_trials / Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Humans / Male Language: En Journal: J Clin Oncol Year: 1997 Type: Article Affiliation country: United States

Search on Google

XML

PubMed Links